Market Place
Sourcing Support
HOOKIPA Pharma Finalizes Oncology Asset Sale To Neotrail
26 Mar 2026 //
GLOBENEWSWIRE
Hookipa Pharma Sells Oncology Assets to Neotrail Therapeutics
03 Feb 2026 //
GLOBENEWSWIRE
HOOKIPA Pharma Completes Sale Of HBV & HIV Assets To Gilead
31 Oct 2025 //
GLOBENEWSWIRE
HOOKIPA Pharma to Voluntarily Delist and Deregister Common Stock
18 Jul 2025 //
GLOBENEWSWIRE
HOOKIPA Issues Statement On Potential Poolbeg Pharma Deal
20 Feb 2025 //
GLOBENEWSWIRE
Poolbeg Pharma and Hookipa Pharma Update on Potential Combination
09 Jan 2025 //
GLOBENEWSWIRE
Hookipa Pharma - FORM 8 (OPD)
08 Jan 2025 //
GLOBENEWSWIRE
Hookipa Updates Shareholders On U.K. Disclosure Requirements
07 Jan 2025 //
GLOBENEWSWIRE
Poolbeg Pharma and HOOKIPA Pharma Update on Potential Combination
07 Jan 2025 //
GLOBENEWSWIRE
HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment
06 Jan 2025 //
GLOBENEWSWIRE
Poolbeg Pharma Combination of Poolbeg and Hookipa Pharma
03 Jan 2025 //
GLOBENEWSWIRE
Hookipa Pharma Reports Q3 2024 Results & Business Updates
14 Nov 2024 //
GLOBENEWSWIRE
Hookipa Pharma to Present Eseba-vec Data at SITC 2024
31 Oct 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Doses Patients with Eseba-vec for Cancer
30 Oct 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
24 Sep 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Announces Board of Directors Changes
30 Aug 2024 //
GLOBENEWSWIRE
Hookipa Pharma To Participate In H.C. Wainwright Conference
28 Aug 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
22 Jul 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
08 Jul 2024 //
GLOBENEWSWIRE
HOOKIPA Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
16 Apr 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
06 Mar 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Provides Update on Business Priorities
29 Jan 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer
16 Jan 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
21 Dec 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma to Report Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Rule 5635(c)(4)
12 Sep 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma to participate in upcoming investor conferences in September
06 Sep 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma to Report Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Rule 5635(c)(4)
10 Jun 2023 //
GLOBENEWSWIRE
HOOKIPA Announces Pricing of $50.0 Million Public Offering of Common Stock
31 May 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma to Report 1Q 2023 FYR & Recent Business Highlights May 11, 2023
04 May 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May
04 May 2023 //
GLOBENEWSWIRE
HOOKIPA to Present a Trial in Progress Prostate Cancer PH 1/2 Trial at ASCO
26 Apr 2023 //
GLOBENEWSWIRE
HOOKIPA to Participate in the Van Lanschot Kempen Life Sciences Conference
19 Apr 2023 //
GLOBENEWSWIRE
HOOKIPA Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
14 Apr 2023 //
GLOBENEWSWIRE
HOOKIPA Reports Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors
13 Mar 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma to Report Fourth Quarter and Full Year 2022 Financial Results
08 Mar 2023 //
GLOBENEWSWIRE
HOOKIPA Achieves $10 Million Milestone Payment for KRAS-Mutated Cancers
13 Feb 2023 //
GLOBENEWSWIRE
HOOKIPA to Present at the SVB Securities Global Biopharma Conference
07 Feb 2023 //
GLOBENEWSWIRE
HOOKIPA Appoints Katia Schlienger as CMO & Malte Peters to Board of Directors
15 Dec 2022 //
GLOBENEWSWIRE
HOOKIPA to Participate in The JMP Securities Hematology and Oncology Summit
30 Nov 2022 //
GLOBENEWSWIRE
HOOKIPA Pharma Announces 3Q 2022 Financial Results &Provides a Business Update
14 Nov 2022 //
GLOBENEWSWIRE
HOOKIPA to Report 3Q 2022 Financial Results & Corporate Updates on Nov 14, 2022
07 Nov 2022 //
GLOBENEWSWIRE
Roche and Hookipa Tie Up in KRAS Inhibitor Deal Valued at Potential $950M
21 Oct 2022 //
BIOSPACE
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September
07 Sep 2022 //
GLOBENEWSWIRE
HOOKIPA Pharma Reports Q2 2022 Rusult and Corporate Updates
11 Aug 2022 //
GLOBENEWSWIRE
FDA accepts HOOKIPA`s Investigational NDA for HB-300
25 Jul 2022 //
GLOBENEWSWIRE
HOOKIPA Announces Executive Leadership Changes
21 Jun 2022 //
GLOBENEWSWIRE
HOOKIPA to Participate in the JMP Securities Life Sciences Conference
09 Jun 2022 //
GLOBENEWSWIRE
HOOKIPA to Present HB-200 PI Results and Recommended PII Dose for HB-202/HB-201
26 May 2022 //
GLOBENEWSWIRE
HOOKIPA Pharma Reports First Quarter 2022 Financial Results
16 May 2022 //
GLOBENEWSWIRE
HOOKIPA Pharma to Report First Quarter 2022 Financial Results on May 16, 2022
09 May 2022 //
GLOBENEWSWIRE
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May
03 May 2022 //
GLOBENEWSWIRE
HOOKIPA announces promotion of Christine D. Baker to Chief Operating Officer
02 May 2022 //
GLOBENEWSWIRE
HOOKIPA Pharma Appoints Tim Reilly, Ph.D. to its Board of Directors
20 Apr 2022 //
GLOBENEWSWIRE
HOOKIPA to Participate in the Kempen Life Sciences Conference
13 Apr 2022 //
GLOBENEWSWIRE
HOOKIPA`s arenaviral immunotherapies induce potent T cell responses in tumour
13 Apr 2022 //
GLOBENEWSWIRE
HOOKIPA Reports Q4 and Full Year 2021 Financial Results
24 Mar 2022 //
GLOBENEWSWIRE
HOOKIPA Announces Promotion of Klaus Orlinger, Ph.D. to Chief Scientific Officer
22 Mar 2022 //
GLOBENEWSWIRE
